Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer

Current Medicinal Chemistry

Volumn 20, Issue 1, 2013, Pages 144-157

  Dulinska Litewka, J ^a   McCubrey, J A ^b   Laidler, P ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

catenin; Akt; Androgen receptor; Androgen insensitive; Androgen sensitive; C Myc; Cyclin D1; Metalloproteinases; Prostate cancer; SiRNA

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BETA CATENIN; CIGLITAZONE; CYCLIN D; CYCLIN G1; GELATINASE A; GELATINASE B; MATRILYSIN; MYC PROTEIN; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C RECEPTOR; UVOMORULIN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CYTOTOXICITY; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANDROGENS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASES, SECRETED; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, ANDROGEN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84872931204     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673130114     Document Type: Article

References (50)

1. American Cancer Society. Atlanta, Georgia, Cancer Facts and Figures http://www.cancer.org (2010).
2. Balk, S.P. Androgen receptor as a target in androgen-independent prostate cancer. Urology, 2002; 60(3 suppl 1), 132-138.
3. Culig, Z.; Georg, B. Androgen axis in prostate cancer. JCB Journal of Cellular Biochemistry, 2006, 99(2), 373-381.
4. Isaacs, J.T. Role of androgens in prostatic cancer. Vitam. Horm. (.N.Y.), 1994, 49, 433-502.
5. Shen, M.M.; Abate-Shen, C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes & Development, 2010, 24, 1967-2000.
6. Garnick, M. B. Prostate cancer : screening, diagnosis, and management. Ann. Intern. Med., 1993, 118, 804-818.
7. Culig, Z.; Hobisch, A.; Hittmair, A.; Peterziel, H.; Cato, A.C.; Bartsch, G.; Klocker, H. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate, 1998, 35, 63-70.
8. van der Kwast, T. H.; Schalken, J.; Ruizeveld de Winter, J. A.; van Vroonhoven, C. C.; Mulder, E.; Boersma, W.; Trapman, J. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer, 1991, 48, 189-193.
9. Laidler, P.; Duliska, J.; Mroziki, S. Does the inhibition of c-myc expression mediates the anti-tumor activity of PPAR'S ligands in prostate cancer cell lines. Arch. Biochem. Bioph., 2007, 462, 1-12.
10. Saxena, P.; Trerotola, M.; Wang, T.; Li, J.; Sayeed, A.; Vanoudenhove, J.; Adams, D.S.; Fitzgerald, T.; Altieri, D.C.; Languino, L.R. PSA regulates androgen receptor expression in prostate cancer cells. Prostate, 2012, 72(7), 769-76.
11. Ming, Z.; Zhu, C.; Sun, J.L.; Weis, W.I.; Sun, Z. The Catenin Binding Protein ICAT Modulates Androgen Receptor Activity Molecular. Endocrinology, 2011, 25, 1677-1688.
12. Alexander, N.R.; Tran, N.L.; Rekapally, H.; Summers, C.E.; Glackin, C.; Heimark, R.L. N-cadherin Gene Expression in Prostate Carcinoma Is Modulated by Integrin-Dependent Nuclear Translocation of Twist1. Cancer Res., 2006; 66, 3365-3369.
13. Jennbacken, K.; Tean, T.; Wang, W.; Gustavsson, H.; Damber, J.; Welén, K. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocrine-Related Cancer, 2010, 17 469-479.
14. Vasioukhin, V.; Fuchs, E. Actin dynamics and cell-cell adhesion in epithelia. Curr. Opin. Cell Biol., 2001, 13, 76-84
15. Nelson, W.J.; Nusse, R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science, 2004, 303, 1483-1487.
16. Kochuparambil, S.T.; Al-Husein, B.; Goc, A.; Soliman, S.; Somanath, P. R. Anticancer Efficacy of Simvastatin on Prostate Cancer Cells and Tumor Xenografts Is Associated with Inhibition of Akt and Reduced Prostate-Specific Antigen Expression. JPE.T. 2011, 336, 496-505.
17. Duliska, J.; Laidler, P.;, M. Comparative analysis of prostate acid phosphatase and prostate specific-antigen mRNA levels in hyperplastic prostate stimulated with steroid hormones and growth factors. Acta Biochim. Polon., 2002, 49, 357-368.
18. Duliska, J.; Gil, D.; Zagajewski, J.; Hartwich, J.; Bodzioch, M.; Dembinska-Kiec, A.; Langmann, T.; Schmitz, G.; Laidler, P. Different effect of beta carotene on proliferation of prostate cancer cells. BBA -Molecular Basis of Disease, 2005, 1740, 189-201.
19. Jach, R.; Duliska-Litewka J.; Laidler P., Szczudrawa A., Kopera K., Szczudlik , Pawlik M., Zajc K., Mak M., Basta A. Expression of VEGF, VEGF-C and VEGFR-2 in insitu and invasive SCC of cervix. Front. Biosci., 2010, 2, 411-423.
20. Sacha, T.; Zawada, M.; Dulinska-Litewka, J.; Lach, Z.; Szostek, M.; Bodzioch, M.; Laidler, P.; Dembiska-Kiec, A.; Florek, I.; Czekalska, S.; Skotnicki, A.B. Beta-carotene regulates the Expression of proapoptotic BAX and CAPN2 in HL-60, U-937 and TF-1 -human acute myeloid leukemia cell lines; microarray, RQ-PCR and Western Blot analysis. Przegld Lekarski, 2011, 68( 4), 258-262.
21. Macabeo-Ong, M.; Ginzinger, D.G.; Dekker, N.; McMillan, A.; Regezi, J.A.;. Wong, D.T.W.; Jordan, R.C.K. Effect of Duration of Fixation on Quantitative Reverse Transcription Polymerase Chain Reaction Analyses. Mod Pathol., 2001, 15, 979-987.
22. Dudzik, P.; Dulinska-Litewka, J.; Wyszko,.E.; Jedrychowska, P.; Barciszewski, J.; Laidler, P. Effects of kinetin riboside on proliferation and proapoptotic activities in human normal and cancer cell lines. Journal of Cellular Biochemistry, 2011, 112, 2115-2124.
23. Verras, M.; Sun, Z. Beta-catenin is involved in insulin-like growth factor 1-mediated transactivation of the androgen receptor. Mol Endocrinol., 2005, 19(2), 391-398.
24. Schrder, F.H. Progress in Understanding Androgen-Independent Prostate Cancer (AIPC): A Review of Potential Endocrine-Mediated Mechanisms. European Urology, 2008, 1129-1137.
25. Cunha, G.R.; Alarid, E.T.; Turner, T.; Donjacour, A.A.; Boutin, E.L.; Foster, B.A. Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors. J. Androl., 1992,.13, 465-475.
26. Attard, G.; Coope, C.S.; de Bono, J.S. Steroid hormone receptors in prostate cancer: A hard habit to break? Cancer Cell, 2009, 16, 458-462.
27. Bonkhoff, H.; Berges, R. From pathogenesis to prevention of castration resistant prostate cancer. Prostate, 2010, 70, 100-112.
28. Linja, M.J.; Savinainen, K.J.; Saramsaki, O.R.; Tammela, T.L.; Vessella, R.L.; Visakorpi, T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res., 2001; 61,3550-3555.
29. Karpf, A.R.; Bai, S.; James, S.R.; Mohler, J.L. Wilson E.M. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AM.P. Mol Cancer Res., 2009, 7, 523-535.
30. Locke, J.A.; Guns, E.S.; Lubik, A.A.; Adomat, H.H.; Hendy, S.C.; Wood, C.A.; Ettinger, S.L.;, Gleave, M.E.; Nelson, C.C. Androgen levels increase by intratumoral de novo stereoidogenesis during progression of castrationresistant prostate cancer. Cancer Res., 2008, 68, 6407-6415.
31. Lih, F.B.; Titus, M.A.; Mohler, J.L.; Tomer, K.B. Atmospheric pressure photoionization tandem mass spectrometry of androgens in prostate cancer. Anal Chem., 2010, 82, 6000-6007.
32. Wang, G.; Sadar, M.D. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer. J Cell Biochem., 2006, 98, 36-53.
33. Mohler, J.L.; Titus, A.; Bai, S.; Kennerley, B.J.; Lih, F.B.; Tomer, K.B.; Wilson, E.M. Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer. Cancer Res.; 2011, 71(4), 1486-1496.
34. Shao-Yong, C.; Wulf, G.; Zhou, X.Z.; Rubin, M.a.; Lu, K.P., Balk, S.P. Activation of -Catenin Signaling in Prostate Cancer by Peptidyl-Prolyl Isomerase Pin1-Mediated Abrogation of the Androgen Receptor-Catenin Interaction. Mol Cell Biol., 2006; 26(3), 929-939.
35. Verras, M.; Sum, Z. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett., 2006, 237, 22-32.
36. Meng-Lei, Z.; Kyprianou, N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J., 2010, 24(3), 769-777.
37. Saleem, M.; Murtaza, I.; Tarapore, R.S.; Suh, Y.; Adhami, V.M.; Johnson, J.J.; Siddiqui, I.A.; Khan, N.; Asim, M.; Hafeez, B.B.; Shekhani, M.T.; Li, B.; Mukhtar, H. Lupeol inhibits proliferation of human prostate cancer cells by targeting -catenin Signaling. Carcinogenesis, 2009, 30(5), 808-817.
38. Chesire, D.R.; Ewing, C.M.; Sauvageot, J.; Bova, G.S.; Isaacs, W.B. Detection and analysis of b-catenin mutations in prostate cancer. Prostate, 2000, 45, 323-334.
39. Yang, G.; Timme, T.L.; Frolov, A.; Wheeler, T.M.; Thompson, T.C. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer, 2005,103, 1186-1194.
40. Wu, J.D.; Haugk, K.; Woodke, L.; Nelson, P.; Coleman, I.; Plymate, S.R. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J. Cell. Biochem., 2006, 99, 392-401.
41. He, X.C.; Yin, T.; Grindley, J.C.; Tian, Q.; Sato, T.; Tao, W.A.; Dirisina, R.; Porter-Westpfahl, K.S.; Hembree, M.; Johnson, T.; Wiedemann, L.M.; Barrett, T.A.; Hood, L.; Wu, H.; Li, L. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet, 2007, 39, 189-198.
42. Rubinfeld, B.; Robbins, P.; El-Gamil, M.; Albert, I.; Porfiri, E.; Polakis, P. Stabilization of -catenin by genetic Defects in melanoma cell lines. Science, 1997, 275, 1790-1792.
43. Daugherty, R.L.; Gottardi. C.J. Phospho-regulation of -catenin adhesion and signaling functions. Physiology, 2007, 22, 303-309.
44. Fang, D.; Hawke, D.; Zheng, Y.; Xia, Y.; Meisenhelder, J.; Nika, H.; Mills, G.B.; Kobayashi, R.; Hunter, T.; Lu, Z. Phosphorylation of -catenin by AKT promotes -catenin transcriptional Activity. J Biol Chem., 2007, 282, 11221-11229.
45. Miyabayashi, T.; Teo, J.L.; Yamamoto, M.; McMillan, M.; Nguyen, C.; Kahn, M. Wnt/b-catenin/CBP signaling maintains long-term murine embryonic stem cell pluripotency. Proc Natl Acad Sci USA, 2007, 104, 5668-5673.
46. Gil, D.; Cioczyk-Wierzbicka, D.; Duliska-Litewka, J.; wawa, K.; McCubrey, J.A.; Laidler, P. The mechanism of contribution of integrin linked kinase (ILK) to epithelial mesenchymal transition (EMT). Advances in Enzyme Regulation Advances in Enzyme Regulation, 2011, 51, 195-207.
47. Caspi, M.; Zilberberg, A.; Eldar-Finkelman, H.; Rosin-Arbesfeld, R. Nuclear GSK-3 inhibits the canonical Wnt signaling pathway in a -catenin phosphorylation-independent manner. Oncogene, 2008, 27:3546-3555.
48. Gardner, S.; Maudsley, S.; Millar, R.P.; Pawson, A.J. Nuclear stabilization of -catenin and inactivation of glycogen synthase kinase-3 by gonadotropinreleasing hormone: targeting Wnt signaling in the pituitary gonadotrope. Mol Endocinology, 2007, 21, 3028-3038.
49. Li, X.; Teitell, M.A.; Lawson, D.A.; Kwon, A.; Mellinghoff, I.K.; Witte, O.N. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. PNAS, 2006, 103(20), 7789 7794.
50. Kampa, M.; Kogia, C.; Theodoropoulos, P.A.; Anezinis, P.;, Charalampopoulos, I.; Papakonstanti, E.A.; Stathopoulos, E.N.; Hatzoglou, A.; Stournaras, C.; Gravanis, A.; Castanas, E. Activation of membrane androgen receptors potentiates the antiproliferative effects of paclitaxel on human prostate cancer cells. Mol Cancer Ther., 2006, 5, 1342-1351.